search
Back to results

NMES Role to Prevent Respiratory Muscle Weakness in Critically Ill Patients and Its Association to Changes in Myokines.

Primary Purpose

Muscle Weakness or Atrophy, Mechanical Ventilation Complication, Electrical Stimulations

Status
Recruiting
Phase
Not Applicable
Locations
Chile
Study Type
Interventional
Intervention
Neuromuscular electrical stimulation (NMES)
Sponsored by
Pontificia Universidad Catolica de Chile
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Muscle Weakness or Atrophy focused on measuring Neuromuscular electrical stimulation, Critical care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Consecutively admission to Christus ICU between March 2021 and December 2021.
  2. Connected to invasive MV within the previous 24-48 hours
  3. Deep sedation [non-cooperative state; Sedation-Agitation Scale (SAS) 1 or 2].
  4. ICU-acquired weakness risk (One of the following risk factors: the need for invasive MV, sepsis, hyperglycemia, APACHE II admission score >13 pts, use of corticosteroids, and/or muscle inactivity due to deep sedation).
  5. Written informed consent provided by patient/surrogate

Exclusion Criteria:

  1. Age < 18 years
  2. Pregnancy
  3. Obesity (Body Mass Index >35 kg/m2)
  4. Pre-existing Neuromuscular diseases (e.g., myasthenia Gravis, Guillain-Barré disease)
  5. Diseases with systemic vascular involvement such as systemic lupus erythematosus.
  6. Use of neuromuscular blockers
  7. Technical obstacles to the implementation of NMES such as bone fractures or skin lesions (e.g., burns)
  8. End-stage malignancy
  9. Presence of cardiac pacemakers
  10. Diagnosis of brain death.

Sites / Locations

  • Pontificia Universidad Católica de ChileRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

NMES group

Control

Arm Description

NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.

Sham NMES will not be provided. Standard care won´t be altered and passive mobilization will be performed according to routine ICU procedures.

Outcomes

Primary Outcome Measures

Change in Tracheal twitch pressure (centimeters of water)
Sub Maximal diaphragmatic strength measured trough tracheal twitch pressure derived from magnetic stimulation of phrenic nerve.
Change in Diaphragmatic thickness fraction (centimeter percentage change)
Diaphragmatic function derived from ultrasonography measurement of diaphragmatic muscle thickness between inspiration and expiration (during twitch manoeuvre)

Secondary Outcome Measures

IL-1 myokine
IL-1 Measured in peripheral blood samples (pg/dL)
IL-6 myokine
IL-6 Measured in peripheral blood samples (pg/dL)
Decorin myokine
Decorin Measured in peripheral blood samples (pg/dL)
Myostatin myokine
Myostatin Measured in peripheral blood samples (pg/dL)
IL-15 myokine
IL-15 Measured in peripheral blood samples (pg/dL)
Brain derived neurotrophic Factor (BDNF) myokine
BDNF Measured in peripheral blood samples (pg/dL)
Change in Diaphragmatic muscle structure (cemtimeters)
Diaphragmatic thickness measured with ultrasonography (Centimeters)
Change in peripheral muscle structure (centimeters)
Muscle layer thickness of vastus intermedius and rectus femoris of the quadriceps, measured with ultrasonography (Centimeters)
Functional outcomes
Mechanical Ventilation time (Hours)
Functional outcomes
ICU length of stay (Days)

Full Information

First Posted
July 20, 2022
Last Updated
September 8, 2022
Sponsor
Pontificia Universidad Catolica de Chile
search

1. Study Identification

Unique Protocol Identification Number
NCT05536531
Brief Title
NMES Role to Prevent Respiratory Muscle Weakness in Critically Ill Patients and Its Association to Changes in Myokines.
Official Title
Role of Neuromuscular Electrical Stimulation to Prevent Respiratory Muscle Weakness in Critically Ill Patients and Its Association to Changes in Myokines Profile. A Randomized Clinical Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 11, 2022 (Actual)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
February 28, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pontificia Universidad Catolica de Chile

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Particularly, muscle respiratory wasting will occur early (18 to 69 hours) in up to 60% of patients with mechanical ventilation (MV), leading rapidly to diaphragmatic weakness, which is associated with prolonged MV use, longer ICU and hospital stay, and higher mortality risk. Sepsis and muscle inactivity, derived from sedation and MV use, are key driver mechanisms for developing these consequences, which can be avoided through early physical activation. However, exercise is limited at the early stages of care, where sedation and MV are needed, delaying muscle activation. Neuromuscular electrical stimulation (NMES) represents an alternative to achieve early muscle contraction in non-cooperative patients, being able to prevent local muscle wasting and, according to some reports, has the potential to shorten the time on MV, suggesting a systemic effect through myokines, a diverse range of cytokines and chemokines secreted by myocytes during muscle contraction. However, no studies have evaluated whether NMES applied to peripheral muscles can exert distant muscle effects over the diaphragm, ameliorating its weakness and if this protective profile is associated with myokine's change in ICU patients. This proposal comprises a randomized controlled study of NMES applied twice daily, for three days, compared to standard care (no NMES). Thirty-two patients will be recruited in the first 48 hours after MV and randomly assigned to the control group or NMES group (16 subjects each). Muscle characterization of quadriceps and diaphragm will be performed at baseline (Day 1, before the first NMES session) and after the last NMES session (morning of day 4). Myokine measurements [IL-1, IL-6, IL-15, Brain-Derived Neurotrophic Factor (BDNF), Myostatin and Decorin], through blood serum obtained from peripheric blood samples, will be performed just before starting NMES (T0) at the end of the session (T0.5), and 2 and 6 hours later (T2 and T6). These myokine curves will be repeated on days 1 and 3 at the first NMES session of the day. The Control group will be assessed in the same way and timing, except that blood samples will be at T0 and T6. Additionally, functional outcomes such as MV time and ICU length of stay will be registered for all patients at ICU discharge. Standard care won´t be altered.
Detailed Description
Critically ill patients hospitalized at Intensive Care Units (ICU) are characterized by an accelerated muscle wasting, which leads to general muscle weakness and loss of physical functions even after discharge. Particularly, muscle respiratory wasting will occur early (18 to 69 hours) in up to 60% of patients with mechanical ventilation (MV), leading rapidly to diaphragmatic weakness, which is associated with prolonged MV use, longer ICU and hospital stay and higher mortality risk. Sepsis and muscle inactivity, derived from sedation and MV use, are key driver mechanisms to developing these negative consequences, which can be avoided through early physical activation. However, exercise is limited at early stages of care, where sedation and MV are needed, delaying muscle activation and favoring a vicious circle. Neuromuscular electrical stimulation (NMES) represents an alternative to achieve early muscle contraction in non-cooperative patients, being able to prevent local muscle wasting and, according to some reports, has the potential to shorten the time on MV, suggesting a systemic effect through myokines, a diverse range of cytokines and chemokines secreted by myocytes during muscle contraction. These factors modulate the function and metabolism of distant organs and can promote muscle cell proliferation and growth in order to maintain muscle structure and function. However, no studies have evaluated whether NMES applied to peripheral muscles can exert distant muscle effects over the diaphragm, ameliorating its weakness, and if this protective profile is associated to myokine's change in critically ill patients. We hypothesize that in mechanical ventilated ICU patients NMES contributes to prevent respiratory muscle weakness when initiated at an early phase of their critical illness, and this effect is associated to acute changes in myokine profile, being able to facilitate discontinuation of MV and decrease ICU length of stay. This proposal comprises a randomized controlled study of NMES applied twice a day, for 3 days, in comparison to standard care (no NMES). Thirty-two patients will be recruited in the first 48 hours after connection to MV, and randomly assigned to either control group or stimulated group (16 subjects for each group). Muscle characterization of quadriceps and diaphragm (Structural ultrasonography evaluation of muscle thickness and tracheal twitch pressure assessment, derived from magnetic stimulation of phrenic nerve, for diaphragmatic strength) will be performed at baseline (Day 1, prior to the first NMES session) and after the last NMES session (morning of day 4). Myokine measurements (IL-1, IL-6, IL-15, BDNF, Myostatin and Decorin), through blood serum obtained from peripheric blood samples, will be performed at baseline 1 hour before NMES (T-1), just before starting NMES (T0), at the end of NMES session (T0.5), and 2 and 6 hours later (T2 and T6). This myokine curves will be repeated on days 1 and 3 at the first NMES session of the day. Control group will be assessed in the same way and timing, with the exception that blood samples will be performed at T0 and T6 of days 1 and 3. Additionally, functional outcomes such as MV time and ICU length of stay will be registered for all patients at ICU discharge. Standard care won´t be altered, performing passive mobilization according to ICU procedures in both groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Muscle Weakness or Atrophy, Mechanical Ventilation Complication, Electrical Stimulations
Keywords
Neuromuscular electrical stimulation, Critical care

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
Analysis of respiratory function (diaphragm) derived from Twitch maneuver and echography (posterior images analysis) will be performed blind to arm assignment. Given sedation, patients will be also be blinded to the intervention.
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NMES group
Arm Type
Experimental
Arm Description
NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Sham NMES will not be provided. Standard care won´t be altered and passive mobilization will be performed according to routine ICU procedures.
Intervention Type
Device
Intervention Name(s)
Neuromuscular electrical stimulation (NMES)
Other Intervention Name(s)
Standard Care
Intervention Description
Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
Primary Outcome Measure Information:
Title
Change in Tracheal twitch pressure (centimeters of water)
Description
Sub Maximal diaphragmatic strength measured trough tracheal twitch pressure derived from magnetic stimulation of phrenic nerve.
Time Frame
Change from begining (Day one) and at the end (Day three)
Title
Change in Diaphragmatic thickness fraction (centimeter percentage change)
Description
Diaphragmatic function derived from ultrasonography measurement of diaphragmatic muscle thickness between inspiration and expiration (during twitch manoeuvre)
Time Frame
Change from begining (Day one) and at the end (Day three)
Secondary Outcome Measure Information:
Title
IL-1 myokine
Description
IL-1 Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
IL-6 myokine
Description
IL-6 Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
Decorin myokine
Description
Decorin Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
Myostatin myokine
Description
Myostatin Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
IL-15 myokine
Description
IL-15 Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
Brain derived neurotrophic Factor (BDNF) myokine
Description
BDNF Measured in peripheral blood samples (pg/dL)
Time Frame
through Study, at begining (Day one) and at the end (Day three). Before and after intervención
Title
Change in Diaphragmatic muscle structure (cemtimeters)
Description
Diaphragmatic thickness measured with ultrasonography (Centimeters)
Time Frame
Change from begining (Day one) and at the end (Day three)
Title
Change in peripheral muscle structure (centimeters)
Description
Muscle layer thickness of vastus intermedius and rectus femoris of the quadriceps, measured with ultrasonography (Centimeters)
Time Frame
Change from begining (Day one) and at the end (Day three)
Title
Functional outcomes
Description
Mechanical Ventilation time (Hours)
Time Frame
through Study completion, an average of 1 month as maximum during follow up
Title
Functional outcomes
Description
ICU length of stay (Days)
Time Frame
through Study completion, an average of 2 month as maximum during follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Consecutively admission to Christus ICU between March 2021 and December 2021. Connected to invasive MV within the previous 24-48 hours Deep sedation [non-cooperative state; Sedation-Agitation Scale (SAS) 1 or 2]. ICU-acquired weakness risk (One of the following risk factors: the need for invasive MV, sepsis, hyperglycemia, APACHE II admission score >13 pts, use of corticosteroids, and/or muscle inactivity due to deep sedation). Written informed consent provided by patient/surrogate Exclusion Criteria: Age < 18 years Pregnancy Obesity (Body Mass Index >35 kg/m2) Pre-existing Neuromuscular diseases (e.g., myasthenia Gravis, Guillain-Barré disease) Diseases with systemic vascular involvement such as systemic lupus erythematosus. Use of neuromuscular blockers Technical obstacles to the implementation of NMES such as bone fractures or skin lesions (e.g., burns) End-stage malignancy Presence of cardiac pacemakers Diagnosis of brain death.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yorschua Jalil, PT, MSc
Phone
96691771
Ext
+56 9
Email
yfjalil@uc.cl
First Name & Middle Initial & Last Name or Official Title & Degree
Alejandro Bruhn, MD, PhD
Phone
23545649
Ext
+56 2
Email
alejandrobruhn@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yorschua Jalil, PT, MSc
Organizational Affiliation
Facultad de Medicina, Pontificia Universidad Católica de Chile
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pontificia Universidad Católica de Chile
City
Santiago
ZIP/Postal Code
8970117
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yorschua Jalil, PT
Phone
96691771
Ext
+569
Email
yfjalil@uc.cl
First Name & Middle Initial & Last Name & Degree
Alejandro Bruhn, MD
Email
alejandrobruhn@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan
Citations:
PubMed Identifier
27310484
Citation
Dres M, Dube BP, Mayaux J, Delemazure J, Reuter D, Brochard L, Similowski T, Demoule A. Coexistence and Impact of Limb Muscle and Diaphragm Weakness at Time of Liberation from Mechanical Ventilation in Medical Intensive Care Unit Patients. Am J Respir Crit Care Med. 2017 Jan 1;195(1):57-66. doi: 10.1164/rccm.201602-0367OC.
Results Reference
result
PubMed Identifier
26167730
Citation
Goligher EC, Fan E, Herridge MS, Murray A, Vorona S, Brace D, Rittayamai N, Lanys A, Tomlinson G, Singh JM, Bolz SS, Rubenfeld GD, Kavanagh BP, Brochard LJ, Ferguson ND. Evolution of Diaphragm Thickness during Mechanical Ventilation. Impact of Inspiratory Effort. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1080-8. doi: 10.1164/rccm.201503-0620OC.
Results Reference
result
PubMed Identifier
25296344
Citation
Dirks ML, Hansen D, Van Assche A, Dendale P, Van Loon LJ. Neuromuscular electrical stimulation prevents muscle wasting in critically ill comatose patients. Clin Sci (Lond). 2015 Mar;128(6):357-65. doi: 10.1042/CS20140447.
Results Reference
result
PubMed Identifier
26475418
Citation
Truong AD, Kho ME, Brower RG, Feldman DR, Colantuoni E, Needham DM. Effects of neuromuscular electrical stimulation on cytokines in peripheral blood for healthy participants: a prospective, single-blinded Study. Clin Physiol Funct Imaging. 2017 May;37(3):255-262. doi: 10.1111/cpf.12290. Epub 2015 Oct 16.
Results Reference
result
PubMed Identifier
20426834
Citation
Routsi C, Gerovasili V, Vasileiadis I, Karatzanos E, Pitsolis T, Tripodaki E, Markaki V, Zervakis D, Nanas S. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care. 2010;14(2):R74. doi: 10.1186/cc8987. Epub 2010 Apr 28.
Results Reference
result

Learn more about this trial

NMES Role to Prevent Respiratory Muscle Weakness in Critically Ill Patients and Its Association to Changes in Myokines.

We'll reach out to this number within 24 hrs